Solid Biosciences
SLDB
58 hedge funds and large institutions have $33.4M invested in Solid Biosciences in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 15 closing their positions.
700% more call options, than puts
Call options by funds: $72K | Put options by funds: $9K
0.05% less ownership
Funds ownership: 3.8% → 3.75% (-0.05%)
13% less funds holding
Funds holding: 67 → 58 (-9)
16% less capital invested
Capital invested by funds: $39.5M → $33.4M (-$6.14M)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.46M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.78M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$503K |
| 4 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$388K |
| 5 |
Franklin Resources
San Mateo,
California
|
+$63.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$3.29M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$3M |
| 3 |
Renaissance Technologies
New York
|
-$273K |
| 4 |
Millennium Management
New York
|
-$250K |
| 5 |
Goldman Sachs
New York
|
-$163K |
SLDB Hedge Fund Activity: Q3 2022 in Review
58 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q3 2022, worth a combined $33.4M — down 16% from $39.5M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SLDB and 6 opened new positions — a net loss of 9 holders — while 18 trimmed existing stakes and 13 added.
The largest buyer was Alyeska Investment Group, adding an estimated $4.46M. The largest seller was Boxer Capital, exiting entirely with an estimated $3.29M sold.
- 58 institutional investors held Solid Biosciences (SLDB) as of Q3 2022, down from 67 in Q2 2022.
- Funds reported $33.4M of Solid Biosciences stock for Q3 2022, down 16% quarter-over-quarter.
- 6 funds opened new Solid Biosciences positions in Q3 2022 and 15 closed out, a net change of -9 holders.
- The largest Solid Biosciences buyer in Q3 2022 was Alyeska Investment Group, an estimated $4.46M added.
- The largest Solid Biosciences seller in Q3 2022 was Boxer Capital, an estimated $3.29M sold.
Based on aggregated 13F filings for Q3 2022.